Pressure Biosciences Inc   (PBIO)
Other Ticker:  
Price: $0.1460 $0.00 -2.341%
Day's High: $0.154 Week Perf: -7.01 %
Day's Low: $ 0.14 30 Day Perf: -33.61 %
Volume (M): 21 52 Wk High: $ 0.83
Volume (M$): $ 3 52 Wk Avg: $0.34
Open: $0.15 52 Wk Low: $0.13

 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 19
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Pressure Biosciences Inc
Pressure Biosciences Inc. is a life sciences company that develops and markets innovative technologies and products for the life science and other industries. The company is primarily focused on the development and commercialization of the proprietary Pressure Cycling Technology (PCT) platform, which uses alternating cycles of hydrostatic pressure to control biomolecular interactions. This technology has a wide range of applications, including sample preparation for next-generation DNA sequencing, protein extraction from cells and tissues, and the development of biomarkers for medical diagnostics. Pressure Biosciences Inc. aims to provide researchers with high-quality, innovative solutions for their sample preparation needs, ultimately driving advancements in various scientific fields.

   Company Address: 14 Norfolk Avenue South Easton 2375 MA
   Company Phone Number: 230-1828   Stock Exchange / Ticker: PBIO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Pressure Biosciences Inc

Pressure Biosciences Inc Reports Mixed Financial Results for Q2 2023, with Modest Revenue Growth

Pressure Biosciences Inc's (PBIO) financial results for the second quarter of 2023 have left analysts and investors with mixed emotions. While the company reported a surge in net deficit and a decline in inventories and accounts receivable, they managed to achieve modest revenue growth. This article will analyze PBIO's financial performance in the context of the overall Laboratory Analytical Instruments industry and the company's stock performance.
Financial Results Analysis:
PBIO reported a per-share deficit of $-0.57 for the second quarter of 2023, an increase from -$0.32 in the same quarter a year ago. Sequentially, the deficit also rose from -$0.46 per share from the prior quarter. This decline in profitability raises concerns among investors and underscores the need for PBIO to address its financial challenges.


Pressure Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com